Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemotherapy

微小残留病 医学 肿瘤科 内科学 诱导化疗 化疗 多元分析 流式细胞术 白血病 免疫学
作者
Rithin Nedumannil,David Ritchie,Ashish Bajel,Ashley P. Ng,Simon Harrison,David Westerman
出处
期刊:European Journal of Haematology [Wiley]
卷期号:110 (2): 168-176
标识
DOI:10.1111/ejh.13890
摘要

Abstract Multi‐parametric flow cytometry (MFC) has a well‐established role in measurable residual disease (MRD) monitoring in patients with B‐lymphoblastic leukemia (B‐ALL). However, the optimal time‐point (TP) for early MRD testing and associated prognostic impact remain undefined in adult B‐ALL patients receiving Hyper‐CVAD induction chemotherapy. To evaluate the utility of MRD analysis after one cycle (TP1) in comparison to MRD analysis after two cycles (TP2) of induction treatment with Hyper‐CVAD chemotherapy, we studied 49 adult B‐ALL patients over a 10‐year period (2010–2020) who had available bone marrow samples for morphological and MFC MRD assessments at the two separate TPs. Median times to TP1 and TP2 relative to start of treatment were 21 and 45 days, respectively. When censored at transplant, achievement of MRD negativity at TP1 was not associated with a statistically significant improvement in either event‐free survival (EFS) ( p = .426) or overall survival (OS) ( p = .335) when compared to patients with MRD positivity. In contrast, achieving MRD negativity at TP2 was associated with a statistically significant improvement in both EFS ( p = ·005) and OS ( p = .047) over patients who remained MRD positive. Multivariate analysis demonstrated that KMT2A ‐rearrangement and MRD positivity at TP2 were the only significant predictors of outcome, correlating with worse EFS and OS. Therefore, in the absence of residual morphologic disease, MRD analysis after one cycle of Hyper‐CVAD induction chemotherapy did not provide additional benefit with regard to risk stratification or correlation with survival outcomes when compared to MRD testing after two cycles of Hyper‐CVAD in adult B‐ALL patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT应助DCOI采纳,获得10
刚刚
刚刚
愉快乐瑶完成签到,获得积分10
1秒前
sure完成签到 ,获得积分10
1秒前
香蕉觅云应助Xide采纳,获得10
1秒前
怎么说应助薄荷草莓糖采纳,获得10
1秒前
meimei完成签到 ,获得积分10
1秒前
Promise完成签到,获得积分20
2秒前
飞小骆驼完成签到,获得积分10
3秒前
3秒前
科研通AI2S应助水濑心源采纳,获得10
3秒前
麻果完成签到,获得积分10
3秒前
英俊的含羞草完成签到,获得积分10
3秒前
尊敬亦寒完成签到,获得积分10
4秒前
和风完成签到 ,获得积分10
5秒前
5秒前
月月鸟完成签到 ,获得积分10
5秒前
刘奶奶的牛奶完成签到,获得积分10
5秒前
6秒前
qwepirt完成签到,获得积分10
6秒前
干净吐司发布了新的文献求助10
6秒前
杨羕完成签到,获得积分10
7秒前
烟花应助WeiBao采纳,获得10
7秒前
木木完成签到,获得积分0
7秒前
英俊亦巧完成签到,获得积分10
7秒前
8秒前
整齐的茗茗完成签到,获得积分10
8秒前
QUA完成签到,获得积分10
8秒前
tomf完成签到,获得积分10
8秒前
zzzz完成签到,获得积分10
9秒前
kiska完成签到,获得积分10
9秒前
二层楼的十三先生完成签到,获得积分10
9秒前
科研疯狂者完成签到,获得积分10
9秒前
惊蛰时分听春雷完成签到,获得积分10
10秒前
脑壳疼完成签到,获得积分10
11秒前
11秒前
CipherSage应助整齐的茗茗采纳,获得10
11秒前
windli完成签到,获得积分10
12秒前
努力向前看完成签到,获得积分10
12秒前
甜美白昼发布了新的文献求助20
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968603
求助须知:如何正确求助?哪些是违规求助? 3513420
关于积分的说明 11168029
捐赠科研通 3248900
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875187
科研通“疑难数据库(出版商)”最低求助积分说明 804676